Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study

Bibliografiska uppgifter
Huvudupphovsmän: Garcia-Manero, G, Daver, N, Xu, J, Chao, M, Chung, T, Tan, A, Wang, Y, Wei, A, Vyas, P, Sallman, D
Materialtyp: Conference item
Språk:English
Publicerad: Elsevier 2021

Liknande verk